Take Control with InsuPad®

Achieve therapeutic target with less hypoglycemia and less insulin

Consensus Statement

Insupad Consensus Statement

 

Insupad is an innovative medical device for diabetes patients using prandial insulin.

 

Based on clinical data and clinical experience Insupad can provide: 1) Better glycemic 

control; 2) Less hypoglycemia; 3) Lower postprandial glucose excursions; and/or 4) 

Lower insulin doses.

 

Insupad may be particularly useful in patients using prandial insulin who have any of the 

following: 1) High prandial insulin requirements; 2) Increased risk of hypoglycemia; 3) 

High postprandial glucose excursions; and/or 4) High glucose variability.

 

Completer roster of the 10 Insuline Scientific Advisory Board members and their 

signatures:

 

Dr. Barry Ginsberg  MD, Ph.D. 

Diabetes Consultants

 

 

Prof.  Dr.  Med. Thomas Haak

Diabetes Klinik Bad Mergentheim 

 

 

Prof. Dr. Lutz Heinemann Phd

Profil Institut fuer Stoffwechselforschung GmbH  

 

 

Prof. David C. Klonoff, MD, FACP

University of California, San Francisco

Diabetes Research Institute,Mills-Peninsula Health Services

 

 

Prof. Itamar Raz, MD

Diabetes Unit, Department of Medicine

Hadassah University Hospital

 

 

Julio Wainstein, MD

The E. wolfsonMedical Center

 

 

Prof. Dr. med. Andreas Pfützner Ph.D.

Geschäftsführer IKFE GmbH

Institut für klinische Forschung und Entwicklung

 

 

William Tamborlane, MD

Department of Pediatrics

Yale University

 

 

Dr. Astrid Tombek 

Diabetes Klinik Bad Mergentheim GmbH 

 

 

Stuart A Weinzimer, MD

Associate Professor of Pediatrics

Yale University School of Medicine

Director, Pediatric Endocrinology Fellowship Program

Medical Director, Type 1 Diabetes Program

 

 

Prof. Lawrence A. Leiter MD FRCPC FACP FAHA

Division of Endocrinology and Metabolism,

St. Michael's Hospital.

Professor of Medicine and Nutritional Sciences,

University of Toronto